SCHEMBL3364443

SCHEMBL3364443

CCn1nc2c(Br)cccc2c1C

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 6/20 0.51
ALDH1A1 P00352 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.39
MAPT P10636 2/20 0.36
GAA P10253 1/20 0.36
LMNA P02545 2/20 0.36
HTT P42858 1/20 0.36
NR1H2 P55055 1/20 0.36
NR1H3 Q13133 1/20 0.36
ALOX15 P16050 1/20 0.35
PRNP P04156 1/20 0.35
ADORA2A P29274 2/20 0.34
ADORA2B P29275 2/20 0.34
CYP1B1 Q16678 1/20 0.34
NPSR1 Q6W5P4 1/20 0.33
GLS O94925 1/20 0.33
ADORA1 P30542 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL359647 0.76 LMNA (0.41) GRM2ALDH1A1MAPTGAALMNA
SCHEMBL20604803 0.72 GRM2 (0.42) GRM2ALDH1A1SMN1; SMN2MAPTGAA
SCHEMBL15995707 0.69 GRM2 (0.41) GRM2ALDH1A1SMN1; SMN2MAPTGAA
SCHEMBL18723388 0.68 ESR1 (0.39) GRM2ALDH1A1SMN1; SMN2NR1H2NR1H3
SCHEMBL14077454 0.68 GRM2 (0.45) GRM2ALDH1A1PRNPCYP1B1ADORA1
SCHEMBL16369689 0.67 LMNA (0.42) ALDH1A1SMN1; SMN2MAPTGAALMNA
SCHEMBL7336437 0.65 ALDH1A1 (0.48) GRM2ALDH1A1MAPTADORA2AADORA1
SCHEMBL18070761 0.64 GRM2 (0.51) GRM2LMNAHTT
SCHEMBL4700240 0.64 GRM2 (0.44) GRM2ALDH1A1SMN1; SMN2GAAHTT
SCHEMBL5763004 0.64 MPO (0.46) ALDH1A1MAPTGAANR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1656353-B1 GABANERGIC MODULATORS HOFFMANN LA ROCHE (CH) 2010-01-27 EP disclosed
CN-100584830-C Gabanergic modulators HOFFMANN LA ROCHE LLC 2010-01-27 CN disclosed
US-7365211-B2 Heterocyclic GABAA subtype selective receptor modulators ROCHE PALO ALTO LLC (US) 2008-04-29 US disclosed
CN-1852897-A Gamma-aminobutyric acid modulators ROCHE PALO ALTO LLC (CH) 2006-10-25 CN disclosed
EP-1656353-A1 GABANERGIC MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2006-05-17 EP disclosed
US-20050101614-A1 For example, 7-(2,4-Dichloro-phenyl)-2-methyl-2H-pyrazolo[4,3-b]pyridine; for treatment of depression, an anxiety disorder, a psychiatric disorder, a learning or cognitive disorder, a sleep disorder, a convulsive or seizure disorder, or pain ROCHE PALO ALTO LLC 2005-05-12 US disclosed
WO-2005016892-A1 GABANERGIC MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2005-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101614-A1 For example, 7-(2,4-Dichloro-phenyl)-2-methyl-2H-pyrazolo[4,3-b]pyridine; for treatment of depression, an anxiety disorder, a psychiatric disorder, a learning or cognitive disorder, a sleep disorder, a convulsive or seizure disorder, or pain HTR2C, GABRA2, GABRA4 GRM2 126/4885ALDH1A1 536/4885SMN1; SMN2 3220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.